"BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib," Blood (Vol: 116, Issue: 17, Page 3278-3285) - 2010
"Major molecular response in CML patients treated with tyrosine kinase inhibitors: The paradigm for monitoring targeted cancer therapy," Oncologist (Vol: 15, Issue: 7, Page 744-749) - 2010
"HFE, SLC40A1, HAMP, HJV, TFR2, and FTL mutations detected by denaturing high-performance liquid chromatography after iron phenotyping and HFE C282Y and H63D genotyping in 785 HEIRS Study participants," American Journal of Hematology (Vol: 84, Issue: 11, Page 710-714) - 2009
"Multi-site PCR-based CMV viral load assessment-assays demonstrate linearity and precision, but lack numeric standardization: A report of the association for molecular pathology," Journal of Molecular Diagnostics (Vol: 11, Issue: 2, Page 87-92) - 2009
"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib," Blood (Vol: 114, Issue: 13, Page 2598-2605) - 2009
"Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia," Journal of Molecular Diagnostics (Vol: 11, Issue: 1, Page 4-11) - 2009
"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials," Blood (Vol: 112, Issue: 8, Page 3330-3338) - 2008
"Authors' Reply:," Journal of Molecular Diagnostics (Vol: 10, Issue: 5, Page 476-) - 2008
"Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia," Leukemia (Vol: 22, Issue: 6, Page 1184-1190) - 2008
"An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy," Journal of Molecular Diagnostics (Vol: 10, Issue: 2, Page 177-180) - 2008
"Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS Study initial screening," American Journal of Hematology (Vol: 83, Issue: 2, Page 126-132) - 2008
"Biological Variability of Transferrin Saturation and Unsaturated Iron-Binding Capacity," American Journal of Medicine (Vol: 120, Issue: 11, Page 999.e1-999.e7) - 2007
"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response," Clinical Cancer Research (Vol: 13, Issue: 20, Page 6136-6143) - 2007
"HFE C282Y homozygotes aged 25-29 years at HEIRS study initial screening," Genetic Testing (Vol: 11, Issue: 3, Page 269-275) - 2007
"An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR," Haematologica (Vol: 92, Issue: 7, Page 970-973) - 2007
"A genome-wide linkage scan for iron phenotype quantitative trait loci: The HEIRS family study," Clinical Genetics (Vol: 71, Issue: 6, Page 518-529) - 2007
"Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study," Blood Cells, Molecules, and Diseases (Vol: 38, Issue: 3, Page 247-252) - 2007
"Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib," Leukemia (Vol: 21, Issue: 3, Page 489-493) - 2007
"BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML," Blood (Vol: 107, Issue: 11, Page 4250-4256) - 2006
"Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in Native Americans and whites in the Hemochromatosis and Iron Overload Screening Study," Clinical Genetics (Vol: 69, Issue: 1, Page 48-57) - 2006
